Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Kintor Pharmaceutical Ltd (9939)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.06 +0.13    +13.98%
04:08:14 - Closed. Currency in HKD ( Disclaimer )
Type:  Equity
Market:  Hong Kong
ISIN:  KYG5273B1077 
  • Volume: 3,524,500
  • Bid/Ask: 1.06 / 1.07
  • Day's Range: 0.92 - 1.09
Kintor Pharma 1.06 +0.13 +13.98%

Kintor Pharmaceutical Ltd Company Profile

 
Get an in-depth profile of Kintor Pharmaceutical Ltd, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

225

Equity Type

ORD

Kintor Pharmaceutical Limited, a clinical-stage biotechnology company, engages in researching, developing, and commercializing therapeutic drugs for dermatology and tumors indications with the unmet medical needs in the People’s Republic of China. Its product candidates include KX-826, a potential topical drug for the treatment of androgenic alopecia and acne vulgaris; and Pruxelutamide (GT0918), a second-generation androgen receptor (AR) for the treatment of metastatic castration-resistant prostate cancer, COVID-19, and AR+ metastatic breast cancer, as well as AR-PROTAC Compound (GT20029). The company is also developing Pruxelutamide (GT0918), a second generation androgen receptor (AR) for the metastatic castration-resistant prostate cancer, COVID-19, and AR+ metastatic breast cancer; GT1708F (Hedgehog/SMO Inhibitor), an inhibitor of the hedgehog signal transduction pathway to treat idiopathic pulmonary fibrosis, and blood cancer; GT0486, an inhibitor of the PI3K/mTOR signalling pathway and a second generation mTOR inhibitor for the treatment of metastatic solid tumours, such as breast cancer, prostate cancer, and hepatocellular carcinoma (HCC); and ALK-1 Antibody (GT90001), an anti-angiogenesis inhibitor and targets a new biological target activin receptor-like kinase-1 globally to treat metastatic hepatocellular carcinoma, a common type of liver cancer, and a variety of solid tumours. Kintor Pharmaceutical Limited was founded in 2009 and is headquartered in Suzhou, the People’s Republic of China.

Contact Information

Address No. 20 Songbei Road Suzhou Industrial Park
Suzhou, 215123
China
Phone 86 51 2626 39909
Fax -

Top Executives

Name Age Since Title
Youzhi Tong 59 2018 Founder, CEO & Executive Chairman
Min Xu 58 2019 Independent Non-Executive Director
Liang Tong 58 2020 Independent Non-Executive Director
Weipeng Gao 48 2021 Non-Executive Director
Wai Yim Yeung 59 2019 Independent Non-Executive Director
Qun Lu 57 2021 CTO & Executive Director
Chengwei Liu 53 2022 Non-Executive Director
Geqi Wei 49 2021 Non-Executive Director
Xiang Ni 54 2023 Chief Medical Officer & Executive Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

9939 Comments

Write your thoughts about Kintor Pharmaceutical Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Jean Charles de Peretti
Jean Charles de Peretti Nov 12, 2021 1:05AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Che passa ? Stock is going down fastly
JAME Megueni
VRAQ Feb 28, 2021 9:27PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
UBS Initiates KINTOR PHARMA-B at ***Buy*** with $28.5 TP.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email